We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+14.79%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$219M
AUM Growth
-$94M
Cap. Flow
-$113M
Cap. Flow %
-51.44%
Top 10 Hldgs %
66.53%
Holding
66
New
5
Increased
5
Reduced
14
Closed
42

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$11.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$9.93M
3
LEGN icon
Legend Biotech
LEGN
+$6.48M
4
ARGX icon
argenx
ARGX
+$4.58M
5
ABBV icon
AbbVie
ABBV
+$3.39M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$28.9M
2
DXCM icon
DexCom
DXCM
+$24.9M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$19.3M
4
WST icon
West Pharmaceutical
WST
+$8.42M
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$8.04M

Sector Composition

Rank Sector Weight
1 Healthcare 93.12%
2 Consumer Staples 0%
3 Energy 0%
4 Financials 0%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$450B
$26M 11.89%
167,807
+23,246
+16% +$3.39M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$37.3B
$18.7M 8.56%
1,794,335
-838,558
-32% -$7.83M
KVUE icon
3
PUT
Kenvue
KVUE
$36.4B
$15M 6.88%
+698,800
New +$14M
REGN icon
4
Regeneron Pharmaceuticals
REGN
$70.9B
$14.1M 6.43%
16,012
-3,997
-20% -$3.29M
GEHC icon
5
GE HealthCare
GEHC
$28.7B
$13.3M 6.07%
171,676
+39,866
+30% +$2.79M
ASND icon
6
Ascendis Pharma A/S
ASND
$17.1B
$12.5M 5.73%
+99,550
New +$9.93M
AVDL
7
DELISTED
Avadel Pharmaceuticals
AVDL
$11.9M 5.42%
839,933
-143,669
-15% -$1.69M
BIIB icon
8
Biogen
BIIB
$30.4B
$11.9M 5.42%
+45,814
New +$11.3M
CTLT
9
DELISTED
CATALENT, INC.
CTLT
$11.8M 5.38%
261,797
-24,202
-8% -$979K
AXSM icon
10
Axsome Therapeutics
AXSM
$11.8B
$10.4M 4.76%
130,738
-11,772
-8% -$787K
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.6B
$10.4M 4.75%
225,564
+53,809
+31% +$1.9M
ARGX icon
12
argenx
ARGX
$53.8B
$9.2M 4.21%
24,182
+9,836
+69% +$4.58M
NTRA icon
13
Natera
NTRA
$38.9B
$8.89M 4.06%
141,847
-132,948
-48% -$6.64M
LEGN icon
14
Legend Biotech
LEGN
$4.31B
$6.15M 2.81%
+102,215
New +$6.48M
MDGL icon
15
Madrigal Pharmaceuticals
MDGL
$12.8B
$5.91M 2.7%
25,524
-8,237
-24% -$1.44M
VRNA
16
DELISTED
Verona Pharma
VRNA
$5.83M 2.66%
293,112
-24,964
-8% -$369K
PRAX icon
17
Praxis Precision Medicines
PRAX
$8.77B
$5.54M 2.53%
248,761
-74,958
-23% -$1.35M
ATXS
18
DELISTED
Astria Therapeutics
ATXS
$4.17M 1.91%
542,945
-55,183
-9% -$305K
AZN icon
19
AstraZeneca
AZN
$262B
$3.96M 1.81%
29,394
+7,277
+33% +$946K
SRRK icon
20
Scholar Rock
SRRK
$6.33B
$3.89M 1.78%
+207,147
New +$2.58M
ARCT icon
21
Arcturus Therapeutics
ARCT
$172M
$3.48M 1.59%
110,470
-98,416
-47% -$2.34M
IMTX icon
22
Immatics
IMTX
$1.31B
$2.9M 1.33%
275,482
-29,492
-10% -$272K
MLTX icon
23
MoonLake Immunotherapeutics
MLTX
$1.64B
$2.87M 1.31%
47,604
-5,696
-11% -$294K
FEMY icon
24
Femasys
FEMY
$9.09M
$35.2K 0.02%
1,808
-2,022
-53% -$49.7K
AM icon
25
Antero Midstream
AM
$10.7B
– –
-13,448
Closed -$161K
1
2 3

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
LS
Leelyn Smith Geneva, Illinois $713M AUM 17.46% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return

Tri Locum Partners's Q4 2023 Portfolio in Review

As of Q4 2023, Tri Locum Partners held 66 positions worth $219M, down 30% from $313M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Tri Locum Partners withdrew a net $113M in Q4 2023, closing 42 positions and reducing 14 holdings. Its most notable exit was Amgen, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Energy.

Against the trend, Tri Locum Partners opened a new position in Biogen worth $11.9M.

  • Tri Locum Partners's largest Q4 2023 buy was Biogen: 45,814 shares worth $11.9M.
  • Tri Locum Partners added most to argenx in Q4 2023, an estimated $4.58M increase.
  • Tri Locum Partners's biggest Q4 2023 reduction was Teva Pharmaceuticals, cutting an estimated $7.83M.
  • Tri Locum Partners fully exited Amgen in Q4 2023, selling an estimated $28.9M.
  • Tri Locum Partners's ten largest holdings make up 67% of its $219M portfolio in Q4 2023.
  • Tri Locum Partners opened 5 new positions and closed 42 in Q4 2023.
  • Tri Locum Partners's portfolio value fell 30% quarter-over-quarter to $219M.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.